Date: 2017-09-11
Type of information: Nomination
Compound: president and chief executive officer
Company: Teva Pharmaceutical (Israel)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On September 11, 2017, Teva Pharmaceutical announced that its board of directors has named Kåre Schultz to become the company’s president and chief executive officer. Mr. Schultz will succeed Dr. Yitzhak Peterburg, who will continue to serve as interim chief executive officer until Mr. Schultz joins the Company. Mr. Schultz will be relocating to Israel and based out of the company’s Petah Tikva headquarters. He most recently served as the president and chief executive officer of Lundbeck00 Prior to this role, he served as chief operating officer of Novo Nordisk.
Financial terms:
Latest news:
Is general: Yes
